Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVER
2023-504486-23-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Regional Et Universitaire De Brest, Ostfold Hospital Trust, Ottawa Hospital Research Institute
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in venous thromboembolism (VTE), pulmonary embolism (PE) and deep vein thrombosis (DVT) comparing Rosuvastatin with Placebo (2 arms). Primary endpoint: Symptomatic recurrent major venous thromboembolism. Planned start Mar 2024; status: authorised.
02
Drugs
rosuvastatin
03
Conditions
venous thromboembolism (VTE)pulmonary embolism (PE)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on 2023-504486-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504486-23-00.